Artificial intelligence supporting cancer patients across Europe—The ASCAPE project

Lazaros Tzelves, Ioannis Manolitsis, Ioannis Varkarakis, Mirjana Ivanovic, Miltiadis Kokkonidis, Cristina Sabater Useros, Thanos Kosmidis, Montserrat Muñoz, Imma Grau, Manos Athanatos, Anamaria Vizitiu, Konstantinos Lampropoulos, Tzortzia Koutsouri, Dimitra Stefanatou, Konstantinos Perrakis, Christina Stratigaki, Serge Autexier, Paris Kosmidis and Antonis Valachis

PLOS ONE, 2022, vol. 17, issue 4, 1-16

Abstract: Introduction: Breast and prostate cancer survivors can experience impaired quality of life (QoL) in several QoL domains. The current strategy to support cancer survivors with impaired QoL is suboptimal, leading to unmet patient needs. ASCAPE aims to provide personalized- and artificial intelligence (AI)-based predictions for QoL issues in breast- and prostate cancer patients as well as to suggest potential interventions to their physicians to offer a more modern and holistic approach on cancer rehabilitation. Methods and analyses: An AI-based platform aiming to predict QoL issues and suggest appropriate interventions to clinicians will be built based on patient data gathered through medical records, questionnaires, apps, and wearables. This platform will be prospectively evaluated through a longitudinal study where breast and prostate cancer survivors from four different study sites across the Europe will be enrolled. The evaluation of the AI-based follow-up strategy through the ASCAPE platform will be based on patients’ experience, engagement, and potential improvement in QoL during the study as well as on clinicians’ view on how ASCAPE platform impacts their clinical practice and doctor-patient relationship, and their experience in using the platform. Ethics and dissemination: ASCAPE is the first research project that will prospectively investigate an AI-based approach for an individualized follow-up strategy for patients with breast- or prostate cancer focusing on patients’ QoL issues. ASCAPE represents a paradigm shift both in terms of a more individualized approach for follow-up based on QoL issues, which is an unmet need for cancer survivors, and in terms of how to use Big Data in cancer care through democratizing the knowledge and the access to AI and Big Data related innovations. Trial registration: Trial Registration on clinicaltrials.gov: NCT04879563.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265127 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 65127&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0265127

DOI: 10.1371/journal.pone.0265127

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().